Sp100
PROMISING POTENTIAL FOR MITHRAMYCIN A, A NOVEL EPIGENETIC ANTINEOPLASTIC AGENT, IN CYTOREDUCTIVE SURGERY FOR PERITONEAL COLORECTAL CANCER
Date
May 18, 2024
Presenter
Tracks
Related Products
DNA-HYPOMETHYLATING AGENT DECITABINE COMBINED WITH CAPTEM CHEMOTHERAPY INDUCES REACTIVATION OF TUMOR SUPPRESSOR GENES VIA DOWNREGULATION OF DNMT1 EXPRESSION IN STC-1 NEUROENDOCRINE TUMOR CELLS
INTRODUCTION: Pancreatic neuroendocrine tumors (PNETs) are a slow-growing, heterogeneous group of neoplasms arising from endocrine tissues of the pancreas. PNETs exhibit a low overall mutational burden, but the genes most commonly mutated are involved in epigenetic regulation…
PROMISING POTENTIAL FOR MITHRAMYCIN A, A NOVEL EPIGENETIC ANTINEOPLASTIC AGENT, IN CYTOREDUCTIVE SURGERY FOR PERITONEAL COLORECTAL CANCER
The benefit of hyperthermic intraperitoneal chemotherapy, in addition to cytoreductive surgery for colorectal cancer, is debated and warrants the assessment of novel therapeutic agents. Colorectal cancer is known to have aberrant epigenetic dysregulation to silence tumor suppressor gene expression…
THE PERFECT STORM: LAPAROSCOPIC TRANSCHOLEDOCHAL BILE DUCT EXPLORATION FOR BILE DUCT BEZOAR IN ADVANCED CIRRHOSIS WITH PORTAL HYPERTENSION
Transcholedochal laparoscopic bile duct exploration is a challenging procedure. Advanced cirrhosis with portal hypertension is associated with unique set of challenges not limited to increased risk of bleeding and fragile liver…
EPIGENETIC DYSREGULATION AND IMMUNE CELL INFILTRATION IN THE PANCREATIC NEUROENDOCRINE TUMOR (PNET) MICROENVIRONMENT: AN IMMUNOHISTOCHEMISTRY (IHC) ANALYSIS
BACKGROUND: DNA Methyltransferase inhibitors (DNMTi) have been found to increase the immunogenicity of cancer cells, reshaping the immune tumor microenvironment while directly reprogramming immune cells…
